Jeffrey Su

Jeffrey Su is the current President at Bioserv. Prior to this, they were the Chief Scientific and Development Officer (CSO/CDO) at Cytovance Biologics from August 2009 to October 2015. In this role, they led Cytovance’s technological and scientific development, and was responsible for tech transfer, process development and trouble shooting for large scale manufacturing. Jeffrey also served as the technical/scientific liaison with clients and business interactions, and led business development activities for emerging markets.

From July 2004 to April 2006, Jeffrey Su was the Sr. Director, Manufacturing and Controls at CancerVax. In this role, they managed all manufacturing and quality related activities that support NPM projects including monoclonal antibody and therapeutic vaccines. Jeffrey was also responsible for developing and managing budgets and contracts with CRO/CMOs, as well as making sure that product specification and project timelines were met. During their time at CancerVax, they increased production scale of D93, an antiagiogenesis antibody, by 50 folds with 4 folds increase in specific productivity; completed tech transfer, process optimization, scale-down and viral removal validation, product (BDS and BP) formulation and stability studies; finished critical assay development, and completed tox and clinical material manufacturing and submitted IND application - all within 12 months. Jeffrey also selected and audited GMP manufacturing facilities capable of mammalian cell culture and microbial fermentation in the US and abroad.

In

Jeffrey Su attended Carleton University and Nankai University.

Some direct reports include Keith Holmgren - Supply Chain Manager, Laura Freeman - Senior Director of QA, and Marianna Tcherpakov - Head of Business Development.